Vedolizumab for treatment of fistulizing crohn's disease
A dosing regimen of humanized α4β7 integrin antagonists like vedolizumab, combined with surgical drainage, effectively treats Crohn's disease fistulas by promoting fistula closure and reducing reliance on corticosteroids.
Patent Information
- Application Number
- JP2024127719
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-11-26
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-19
AI Technical Summary
Current treatments for Crohn's disease with fistulas, such as surgical and medical therapies, are limited in efficacy and often result in recurrence or intolerance, particularly for patients with perianal fistulas.
Administration of humanized α4β7 integrin antagonists, specifically vedolizumab, following a specific dosing regimen that includes intravenous and subcutaneous infusions, combined with surgical placement of a drainage line, to induce healing of fistulas.
The regimen effectively closes draining fistulas in a significant proportion of patients, reducing the need for drainage pads and potentially eliminating corticosteroid use, while maintaining fistula closure for extended periods.
Smart Images

Figure 2024161423000012 
Figure 2024161423000013 
Figure 2024161423000014
Abstract
Description
[Technical field]
[0001] Related Applications This application is a joint venture of U.S. Provisional Application No. 62 / 084,815, filed November 26, 2014. The entire contents of the above application are incorporated herein by reference. [Background technology]
[0002] background For example, inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease (CD), are characterized by gastrointestinal IBD can be a debilitating and progressive disease involving inflammation of the lining of the body. Treatment of IBD includes anti-inflammatory drugs (e.g. corticosteroids and sulfasalazine), immunosuppressants (e.g., 6-mercapto topramine, cyclosporine, and azathioprine) and surgery (e.g., colectomy). Podolsky, New Engl. J. Med., 325:928-937 (1991) and Podolsky, New Engl. J. Med., 325:100 8-1016 (1991). As the disease progresses, treatment involves gradually reducing the risk of side effects. These patients then proceed to a regimen that exposes them to increased risk and loss of quality of life.
[0003] In contrast to the diffuse, superficial, persistent inflammation restricted to the colon in ulcerative colitis, The inflammation in Crohn's disease can be localized and transmural, affecting the gastrointestinal (GI) tissue from the mouth to the anus. I) Any segment of the duct may be involved. The prevalence of CD is approximately 150 / US population. The prevalence of neutrophils in the United States is about 100,000 and about 125 / 100,000 population in Western Europe. The hallmark of CD is the development of a chronic inflammatory infiltrate composed of cells and macrophages. CD is currently curable medically and surgically. I can't heal.
[0004] Fistulas are chronic tracts of granulation tissue between two epithelial linings. CD with fistulas is a chronic tract of granulation tissue between two epithelial linings. CD is a distinct disease subtype that affects many individuals. Patients with CD who have fistulizing anal pain Patients experience symptoms of purulent discharge and incontinence, leading to high morbidity and impaired quality of life. It can be done.
[0005] The fistula(s) rarely heal spontaneously but usually require medical therapy or surgery. Although a variety of medical and surgical options are available for CD, the fistula(s) Patients with perianal CD have limited treatment options. The role of corticosteroids has not been demonstrated. Antibiotics may contribute to healing, but antibiotics are not effective. Thiopurine is recommended as adjunctive therapy for fistulizing Crohn's disease. It may have modest efficacy in treating tumor necrosis, but the data are limited or confounding. Infliximab, a tumor necrosis factor (TNF) antagonist monoclonal antibody, was evaluated in two prospective randomized controlled trials. Studies have shown it to be effective in healing fistula(s).
[0006] Management of perianal CD is challenging and requires a comprehensive approach, including both medical and surgical treatments. Since it is often necessary, a comprehensive treatment plan including administration of anti-α4β7 antibodies, such as vedolizumab, is recommended. There is a need to treat surgical patients who can benefit from curative therapy. Summary of the Invention [Problem to be solved by the invention]
[0007] Summary of the Invention The present invention relates to the use of antagonists of α4β7 integrin, e.g., anti-α4β 7 regarding treatment with antibodies (e.g., vedolizumab). [Means for solving the problem]
[0008] Thus, in a first aspect, the present invention provides a method for treating a human suffering from fistulizing Crohn's disease. A method of treating a patient, comprising administering to a patient suffering from fistulizing Crohn's disease a human α4β7 antibody. A humanized antibody having binding specificity for integrin is administered by the following dosing regimen: a) intravenous infusion b) an initial dose of 300 mg of humanized antibody as an intravenous infusion approximately 2 weeks after the initial dose; and a second subsequent dose of 300 mg of the humanized antibody; c) followed by an intravenous infusion approximately 6 weeks after the initial dose. and then a third subsequent dose of 300 mg of the humanized antibody intravenously about 10 weeks after the initial dose. e) a fourth subsequent dose of 300 mg of humanized antibody as an infusion; f) followed by intravenous administration approximately 14 weeks after the initial dose. f) a fifth subsequent dose of 300 mg of humanized antibody as an intravenous infusion; f) followed by a fifth subsequent dose of 300 mg of humanized antibody as an intravenous infusion; of humanized antibody as an intravenous infusion every 8 weeks after the 6th dose and subsequent doses of 300 mg a humanized antibody; The administration regimen included the use of a surgically placed drainage line (seton) prior to administration of and furthermore, a humanized antibody has an antigen-binding region of non-human origin and an antigen-binding region of human origin. and at least a portion of an antibody, the humanized antibody having binding specificity for the α4β7 complex. The antigen-binding region has the following CDRs: light chain: CDR1 SEQ ID NO: 7, CDR2 SEQ ID NO: 8, and and CDR3 SEQ ID NO:9; and heavy chain: CDR1 SEQ ID NO:4, CDR2 SEQ ID NO:5 and CDR3 SEQ ID NO:6 DR3 SEQ ID NO: 6. In some embodiments, the fistula(s) is / are perianal Peripheral fistula(s)
[0009] Fistula(s) healing was assessed by magnetic resonance imaging (MR) of fistula(s) healing at 30 weeks. I) Measurable by assessment. In some embodiments, at least 50% of the fistulas drain In some embodiments, 100% of the draining fistulas are closed. for treatment with at least one of a modulator, a tumor necrosis factor alpha antagonist, and a combination thereof may have had a lack of adequate response or loss of response to In some embodiments, the patient is unable to tolerate corticosteroids. may have had a severe response to corticosteroids or may have been intolerant to corticosteroids; He showed dependence on corticosteroids.
[0010] In some embodiments, the Crohn's disease is moderately to severely active Crohn's disease. In one embodiment, the Crohn's disease is severely active.
[0011] The dosing regimen results in a reduction, elimination, or reduction and elimination of drainage pads used by the patient. It is possible.
[0012] In some embodiments, the humanized antibody is administered to the patient in about 30 minutes.
[0013] In some embodiments, the humanized antibody is reconstituted from a lyophilized formulation.
[0014] In some embodiments, the humanized antibody is reconstituted into a stable liquid formulation.
[0015] In some embodiments, the patient is diagnosed with a lack of adequate response to corticosteroids or In some embodiments, the immunomodulatory agent is azoxymethane. ophrase, 6-mercaptopurine, or methotrexate.
[0016] Treatment can be measured by the patient's PDAI or CDAI score. In an embodiment, the patient's PDAI score is reduced by at least 3 points from baseline.
[0017] The humanized antibody may have a heavy chain variable region sequence of amino acids 20-140 of SEQ ID NO:1.
[0018] The humanized antibody may have a light chain variable region sequence of amino acids 20-131 of SEQ ID NO:2.
[0019] The humanized antibody comprises a heavy chain comprising amino acids 20 to 470 of SEQ ID NO:1 and a heavy chain comprising amino acids 20 to 470 of SEQ ID NO:2. In some embodiments, the humanized antibody may have a light chain comprising amino acids 20 to 238. It is.
[0020] In another aspect, the present invention provides a method for treating a human patient suffering from fistulizing Crohn's disease. The method comprises administering to a patient suffering from fistulizing Crohn's disease a human α4β7 integrin A humanized antibody having binding specificity for a) a dose of 300 mg of humanized antibody; b) followed by a second dose as an intravenous infusion approximately two weeks after the initial dose. a subsequent dose of 300 mg of humanized antibody; c) followed by a third dose as an intravenous infusion approximately 6 weeks after the initial dose. a subsequent dose of 300 mg of the humanized antibody; d) followed as an intravenous infusion approximately 14 weeks after the initial dose. a fourth subsequent dose of 300 mg of humanized antibody; e) followed by a fifth subsequent dose of humanized antibody as needed. the fifth and subsequent doses of 300 mg of humanized antibody as an intravenous infusion every eight weeks after administration; Thus, the method includes administering to the human patient a surgically placed drainage line prior to administration of the antibody. and wherein the administration regimen induces fistula(s) healing; and further wherein the humanized antibody is a human antibody of non-human origin. and at least a portion of an antibody of human origin, the humanized antibody comprising an antigen-binding region of α4β7 and has binding specificity for the complex, the antigen-binding region comprising the following CDRs: light chain: CDR1 sequence No. 7, CDR2 SEQ ID NO: 8 and CDR3 SEQ ID NO: 9; and heavy chain: CDR1 SEQ ID NO: 4. The method according to claim 1, comprising CDR2 SEQ ID NO:5 and CDR3 SEQ ID NO:6. , the fistula(s) are perianal fistula(s).
[0021] Fistula(s) healing was assessed by magnetic resonance imaging (MR) of fistula(s) healing at 30 weeks. I) Measurable by assessment. In some embodiments, at least 50% of the fistulas drain In some embodiments, 100% of the draining fistulas are closed. [Brief description of the drawings]
[0022] [Figure 1] Graph showing mean time to fistula closure in patients in the maintenance intent to treat (ITT) population with fistulizing disease. Patients in the placebo (PBO) group received vedolizumab (VDZ) at weeks 0 and 2 of the 6-week induction phase. HR, hazard ratio (95% CI). All patients in the maintenance ITT population received induction treatment with VDZ. Patients in the VDZ / PBO maintenance group received VDZ during the 6-week induction phase followed by PBO for the 46-week maintenance phase. Patients in the VDZ / VDZ maintenance group received VDZ during induction and VDZ every 8 weeks or every 4 weeks during maintenance. [Diagram 2] Graph showing fistula closure by study visit for patients with ≥ 1 fistula at week 0 (maintenance ITT population). Abbreviations: PBO, placebo; VDZ, vedolizumab. Patients in the VDZ / PBO group received VDZ for a 6-week induction phase followed by PBO for a 46-week maintenance phase. Patients in the VDZ / VDZ group received VDZ during induction and VDZ every 8 weeks or every 4 weeks during maintenance. [Diagram 3]Graph showing mean time to draining fistula opening in patients without draining fistula at week 0 (maintenance ITT population). Abbreviations: PBO, placebo; VDZ, vedolizumab. Patients in the VDZ / PBO group received VDZ during a 6-week induction phase followed by PBO during a 46-week maintenance phase. Patients in the VDZ / VDZ group received VDZ during induction and VDZ every 8 weeks or every 4 weeks during maintenance. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023] Detailed Description The present invention relates to a drainage line having at least one fistula and surgically implanted prior to drug treatment. The present invention relates to a method for treating a patient with Crohn's disease who has had one or more Crohn's fistulas ( To maximize benefit to patients with multiple ALK-positive or ALK-negative ... Designing combination methods with glioma antagonists, such as anti-α4β7 antibodies (e.g., vedolizumab) In some embodiments, the treatment comprises remission of Crohn's disease. The fistula(s) is / are a perianal fistula. In some embodiments, the fistula(s) is / are a perianal fistula. or a peritoneal fistula. In some embodiments, the fistula(s) is not a rectovaginal fistula.
[0024] One aspect of the invention is an α4β7 inactivator for use in the treatment of a subject with fistulizing Crohn's disease. and a fibromyalgia antagonist (e.g., vedolizumab), and the subject's fistula(s) are I'm receiving a call.
[0025] definition The term "pharmaceutical formulation" refers to an anti-α4β7 antibody in a form in which the biological activity of the antibody can be effective. and the like, and is not tolerated by the subject to whom the formulation is to be administered. This refers to formulations that do not contain additional ingredients that are significantly toxic.
[0026] The cell surface molecule "α4β7 integrin," or "α4β7," is a fusion protein that binds the α4 chain (CD It is a heterodimer of the β7 chain (ITGB7) and the β4 chain (ITGA4). It forms heterodimers with the integrin chains α4β1 or α E Formation of β7 The human α4 and β7 genes (GenBank, National Center for Biotechnology Information,Be Thesda, MD) RefSeq accession numbers NM_000885 and NM_000889 ) is expressed by B and T lymphocytes, especially memory CD4+ lymphocytes. The integrin archetype α4β7 can exist in either a resting or activated state Ligands for α4β7 include vascular cell adhesion molecule (VCAM), fibronectin, and α4β7. These include the mucosal addressins (MAdCAMs (e.g., MAdCAM1)).
[0027] An "α4β7 antagonist" is a drug that antagonizes or reduces the function of the α4β7 integrin. The antagonist is a molecule that inhibits or blocks the binding of the α4β7 integrin and one of its ligands. α4β7 antagonists can antagonize the interaction with the heterodimer or α4β7 intermolecular complexes. It can bind to either chain of tegrin in a complex that requires both chains, or it can bind to the α4β7 antagonist The antagonist may bind to a ligand such as MAdCAM. The antibody may be an antibody capable of binding to an α4β7 integrin, such as an anti-α4β7 integrin antibody or an "anti-α4β7 antibody." In some embodiments, the α4β7 antagonist, such as an anti-α4β7 antibody, is an “antibody against the α4β7 complex.” It has a "binding specificity similar to that of α4β7, but not to α4β1 or αEβ7. .
[0028] The term "antibody" or "antibodies" is used broadly herein and specifically refers to , full length antibody, antibody peptide(s) or immunoglobulin(s), monoclonal Antibodies, polyclonal antibodies, at least two full-length antibodies (e.g., antibodies against different antigens or epitopes) A multispecific antibody (e.g., a bispecific antibody) formed from a plurality of antigen-binding domains (each portion of the antibody containing an antigen-binding region of the antibody to a bispecific antigen-binding domain). and any of the above, e.g., antibodies or antibodies from which they are derived. Individual antigen-binding fragments of any of the antibodies, e.g., dAbs, scFv, Fab, F(ab) 2. Human antibodies, humanized antibodies derived from non-human species, and recombinant antigen-binding forms, including Fab , e.g. monobodies and diabodies This covers everything including.
[0029] The term "human antibody" includes antibodies having sequences derived from human germline immunoglobulin sequences, e.g. For example, transgenic mice carrying human immunoglobulin genes (e.g., genetically engineered The mice used were XENOMOUSE (Abgenix, Fremont, CA), HUMA B-MOUSE (registered trademark), KIRIN TC MOUSE (trademark) introduced chromosome (tr anschromosome mouse, KMMOUSE (registered trademark) (MEDAREX, Princeton, NJ), Human phage display library, Human bone marrow Included are antibodies derived from myeloma cells, or human B cells.
[0030] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogenous population of antibodies. This refers to the antibodies that are produced in a population of monoclonal antibodies. Identical and / or binding to the same epitope, except for possible variants that may arise during life. Typically, the variants are present in small amounts. In contrast to polyclonal antibody preparations, which contain a variety of antibodies raised against each Clonal antibodies are directed against a single determinant on the antigen. "Non-specific" refers to the characterization of an antibody as being obtained from a substantially homogenous population of antibodies, and It should not be construed as requiring production of antibodies by any particular method. For example, use in accordance with the present invention The first monoclonal antibodies were published by Kohler et al., Nature, 25 6:495 (1975), or or by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). The term "monoclonal antibody" refers to, for example, the antibody described in Clackson et al. Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991) was used to The antibodies can be isolated from large antibody libraries.
[0031] The monoclonal antibodies of the present invention may, in particular, comprise a portion of the heavy and / or light chain that is specific to a particular species. It is derived from or is identical to the corresponding sequence in an antibody belonging to a particular antibody class or subclass. one or more of the strands are homologous thereto, while the remainder of the strand(s) is / are from another species or is identical to or has a corresponding sequence in an antibody belonging to another antibody class or subclass The present invention relates to "chimeric" antibodies which are homologous thereto, as well as fragments of such antibodies (if they are desired). (U.S. Pat. No. 4,816,567; and Morris on et al.,Proc.Natl.Acad.Sci.USA,81:6851 Chimeric antibodies of interest herein include those derived from non-human primates ( For example, variable domain antigen-binding sequences derived from Old World Monkey, Ape, etc. and "primatized" antibodies that contain human constant region sequences. .
[0032] The "antigen-binding fragment" of the humanized antibody prepared in the formulation of the present invention is an anti-α4β 7 antibody. For example, the antibody of vedolizumab The original binding fragment contains amino acid residues 20 to 131 of the humanized light chain sequence of SEQ ID NO:2. Examples of such antigen-binding fragments include the Fab fragments of humanized antibodies known in the art. Examples of the F(ab')2 fragment include F(ab')2 fragment, Fab' fragment, scFv and F(ab')2 fragment. Antigen-binding fragments of the humanized antibodies of the present invention can be prepared by enzymatic cleavage or recombinantly. For example, papain or pepsin cleavage can be used to prepare glycerol-containing glycerol. Fab or F(ab')2 fragments can be generated. The antibody gene was designed to have one or more termination codons introduced into the gene, allowing the production of various truncated forms of the antibody. For example, the CH of the heavy chain can be I DNA encoding the domain and hinge region A recombinant construct encoding the heavy chain of the F(ab')2 fragment was prepared to contain the A sequence. In one embodiment, the antigen-binding fragment can be designed to bind to the α4β7 and one or more ligands of the mucosal addressin MAdCAM (e.g., MA Inhibits binding to dCAM1) and fibronectin.
[0033] Papain digestion of antibodies produces two identical antigen-binding fragments called "Fab" fragments. Each of these has a single antigen-binding site and a residual "Fc" fragment. , its name reflects its ability to crystallize easily. Pepsin treatment separates the two antigens An F(ab')2 fragment is generated that has the binding site and is still capable of cross-linking antigen.
[0034] "Fv" refers to one heavy chain variable domain and one light chain variable domain in a non-covalent association. It is an antibody fragment consisting of a dimer.
[0035] The Fab fragment contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. The Fab' fragment also contains the antibody human IgG1 domain at the carboxy terminus of the heavy chain CH1 domain. By adding several residues, including one or more cysteines from the range region, the Fab Fab'-SH is defined herein as a fragment of the cysteine residues of the constant domains. Symbolic table for Fab' in which group(s) have at least one free thiol group F(ab')2 antibody fragments initially have hinge cysteines between them. Other chemical coupling of antibody fragments has been reported. The ring is also known.
[0036] "Single-chain Fv" or "scFv" antibody fragments are fragments of the V H and V L Domain In one embodiment, the Fv polypeptide comprises a polypeptide chain having a length of at least one amino acid sequence, and these domains are present in a single polypeptide chain. Petite is V H and V L The scFv further comprises a polypeptide linker between the domains. For a review of scFvs, see Pluckt et al. hun in The Pharmacology of Monoclonal An tibodies,vol.113,Rosenburg and Moore eds , Springer-Verlag, New York, pp.269-315(199 Please refer to 4).
[0037] The term "diabody" refers to a small antibody fragment that has two antigen-binding sites. This fragment is a polypeptide chain (V H -V L ) in the variable light domain (V L ) The variable heavy domain (V H ) that allows pairing between the two domains on the same chain. By using a linker that is too short for the domain to be linked to a complementary domain on another strand, Diabodies are, for example, EP404. ,097; WO93 / 11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993) Fully documented.
[0038] A "full-length antibody" refers to an antibody that contains an antigen-binding variable region as well as a light chain constant domain (C L ) and heavy chain constant domain Main C H1 , C H2 and C H3 The constant domain is a native sequence constant domain. may be a human native sequence constant domain or an amino acid sequence variant thereof. In one embodiment, the full length antibody has one or more effector functions.
[0039] As used herein, an "amino acid sequence variant" antibody is an antibody that has an amino acid sequence that differs from the primary species antibody. Typically, the amino acid sequence variant has at least about 7 amino acid sequences similar to the major species antibody. 0%, at least about 80%, at least about 85%, at least about 90%, or at least The amino acid sequence variants will have approximately 95% homology to the amino acid sequence of the primary antibody. Substitutions, deletions, and / or additions at specific positions within or adjacent to the nucleic acid sequence, but not The original binding activity is maintained. The effect of changes in the constant region sequence of the antibody on antigen-binding activity There will be fewer changes in the variable regions. In the variable regions, amino acid sequence variants , at least about 90% homologous to the major species antibody, at least about 95% homologous, at least about 97% It may be homologous, at least about 98% homologous, or at least about 99% homologous.
[0040] "Homology" is determined by aligning sequences and, if necessary, aligning amino acid sequence variants. It is defined as the percentage of residues that are identical after inserting a loop to achieve the maximum percent homology. Methods and programs for this alignment are well known in the art.
[0041] A "therapeutic monoclonal antibody" is an antibody used to treat human subjects. Illustrative therapeutic monoclonal antibodies include anti-α4β7 antibodies.
[0042] A "glycosylation variant" antibody herein refers to an antibody that is a glycosylation variant of a glycosylation variant of a major species antibody. The carbohydrate moiety of the antibody is one or more carbohydrate moieties attached thereto that are different from the carbohydrate moiety of the antibody described herein. Examples of glycosylation variants in the Fc region include those that have an alternative glycosylation structure to the G0 oligosaccharide structure. In addition, antibodies with G1 or G2 oligosaccharide structures attached to one or two of their light chains or two carbohydrate moieties attached to one or two heavy chains of the antibody; and combinations of glycosylation changes.
[0043] Antibody "effector functions" are determined by the Fc region of the antibody (either the native sequence Fc region or the amino acid sequence The term "antibody effector function" refers to a biological activity that can be attributed to a variant Fc region. C1q binding; complement-dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated Cytotoxicity (ADCC); phagocytosis; under cell surface receptors (e.g. B cell receptor: BCR) To evaluate the ADCC activity of a molecule of interest, ADCC assays, such as those described in U.S. Pat. No. 5,500,362 or 5,821,333. You may do what is described in No. 7.
[0044] Full length antibodies can be divided into different "classes" depending on the amino acid sequence of the constant domain of their heavy chains. There are five main classes of full-length antibodies: IgA, IgD, IgE, There are IgG and IgM, some of which are further divided into "subclasses" (isotypes), e.g. For example, they can be divided into IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy chain constant domains corresponding to the different classes of antibodies are α, δ, ε, γ, and μ. The subunit structures and three-dimensional configurations of different classes of antibodies are well known. .
[0045] The "light chains" of antibodies from any vertebrate species can be identified by the amino acid sequence of their constant domains. Based on the nature of the phenotype, they are assigned to one of two distinct types, called kappa (κ) and lambda (λ). It can be assigned.
[0046] The term "hypervariable region" as used herein refers to the amino acid sequence of an antibody which is responsible for antigen binding. The hypervariable regions are commonly referred to as "complementarity determining regions" or "CDRs" (e.g., Residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) of the light chain variable domain ) and residues 31-35 (H1), 50-65 (H2) and 95- 102(H3);Kabat et al.,Sequences of Protei ns of Immunological Interest,5th Ed.Publ ic Health Service,National Institutes of Health, Bethesda, Md. (1991)) and / or "hypervariable loop " (e.g., residues 26-32 (L1), 50-52 (L2) of the light chain variable domain) 2) and 91-96 (L3) and residues 26-32 (H1), 53 of the heavy chain variable domain ~55(H2) and 96~101(H3); Chothia and Lesk JM Ol. Biol. 196:901-917 (1987)). " or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined. The hypervariable region or its CDRs can be transferred from one antibody chain to another antibody chain or to another protein. and transfer the antigen-binding specificity to the resulting (composite) antibody or binding protein. Can be given.
[0047] "Humanized" forms of non-human (e.g., rodent) antibodies contain minimal sequence derived from the non-human antibody. For the most part, humanized antibodies are chimeric antibodies that are made up of human immunoglobulins (recipient antibodies). and residues from the recipient hypervariable region provide the desired specificity, affinity, and potency. The donor antibody may be a highly soluble donor antibody from a non-human species, such as mouse, rat, rabbit or non-human primate. In some cases, the residues are replaced with residues from a framework region (F R) residues are replaced by corresponding non-human residues. These modifications may be made to improve the properties of the antibody. Generally, humanized antibodies contain at least one, and typically two, variable fragments. The present invention will include substantially all of the domains, and all or substantially all of the hypervariable loops are corresponding to those of a non-human antibody, and all or substantially all of the FRs are those of a human antibody sequence. A humanized antibody optionally contains an antibody constant region (Fc), typically that of a human antibody. For further details, see Jones et al. .,Nature 321:522-525(1986);Riechmann et. al., Nature 332:323-329 (1988); and Presta, Cu. See, e.g., rr. Op. Struct. Biol. 2:593-596 (1992). .
[0048] An "affinity matured" antibody has one or more alterations in one or more hypervariable regions thereof resulting in , which improves the affinity of the antibody for the antigen compared to a parent antibody lacking the alteration(s). In one embodiment, the affinity matured antibody has nanomolar or picomolar affinity to the target antigen. Affinity matured antibodies can be produced by any method known in the art. Marks et al. Bio / Technology 10: 779-783 (1992) describes the affinity composition of VH and VL domains by shuffling. Random mutagenesis of CDR and / or framework residues has been described. As described in: Barbas et al. Proc Nat. Acad. Sc i,USA 91:3809-3813(1994);Schier et al.Ge ne 169:147-155(1995);Yelton et al.J.Immu nol.155:1994-2004(1995);Jackson et al.,J Immunol.154(7):3310-9(1995); and Hawkins e t al., J. Mol. Biol. 226:889-896 (1992).
[0049] An "isolated" antibody is one that has been identified and separated and / or recovered from a component of its natural environment. In certain embodiments, the antibody has (1) greater than 95% by weight chromatin as determined by the Lowry method. or up to 99% by weight or more, or (2) Spinning Cup Sequenator ( Using a spinning cup sequenator, we cloned the N-terminal or internal amino acid sequence. or (3) Coomassieve Homogeneity by SDS-PAGE under reducing or non-reducing conditions using Lou or silver staining An isolated antibody will be purified to the extent possible. The term "antibody in situ" includes antibodies in recombinant cells, since they will no longer be present in the isolated cells. The antibody is prepared by at least one purification step.
[0050] "Treatment" refers to both therapeutic and prophylactic or preventative measures. This includes not only those who already have the disease, but also those who wish to prevent the disease or its recurrence. Thus, the patient to be treated herein, e.g., a human, is diagnosed with a disease. As used herein, the term may refer to a condition that is caused by a disease, or may be predisposing or susceptible to a disease. The terms "patient" and "subject" are used interchangeably.
[0051] The antibodies that are formulated are substantially pure and preferably substantially homogeneous (i.e., A "substantially pure" antibody is one that is free of contaminating proteins and the like. At least about 90% by weight, at least about 95% by weight, or 97% by weight, based on the total weight A "substantially homogeneous" antibody refers to a composition that contains, by weight of total protein, Based on this, at least about 99% by weight of the protein is a specific antibody, e.g., an anti-α4β7 antibody. The term "composition" refers to a composition comprising a protein which is
[0052] As used herein with respect to ulcerative colitis subjects, "clinical remission" refers to a complete majority response of 2 points or less. Mayo score and individual subscores not greater than 1 point "Clinical remission" for Crohn's disease is defined as a CDAI score of 150 or less.
[0053] As used herein with respect to Crohn's disease subjects, "clinical response" refers to the time course of a clinical response from baseline (week 0) to This refers to a reduction of 70 or more points in CDAI score from
[0054] As used herein, "treatment failure" refers to the progression of disease, the absence of any therapeutic effect for the treatment of Crohn's disease, or Rescue medication refers to the need for rescue medication or surgery. or any new drug therapy required to treat unresolved Crohn's disease symptoms. or any increase in the dose of baseline medication (antidiarrheal medications for control of chronic diarrhea) other than).
[0055] Anti-α4β7 integrin, a humanized monoclonal antibody with binding specificity for the α4β7 integrin The α4β7 antibody vedolizumab is an anti-inflammatory drug for the treatment of moderately to severely active ulcerative colitis (UC). Vedolizumab is indicated for the treatment of patients with inflammatory bowel disease (IBD) and Crohn's disease (CD). Other biologic agents currently marketed for the treatment of IBD, such as natalizumab and It has a novel intestine-selective mechanism of action that differs from that of tumor necrosis factor α (TNFα) antagonists. By binding to α4β7 expressed on the cell surface, vedolizumab acts as an α4β7 antagonist. Anti- and memory gut-homing T lymphocyte subsets and mucosal epithelial cell expression It blocks the interaction with MAdCAM1. Migration of these cells into inflamed intestinal tissue is inhibited.
[0056] The pharmacokinetics of other therapeutic monoclonal antibodies used to treat CD have been previously reported. Several factors have been implicated: the presence of anti-drug antibodies, sex, body size, and concurrent use of immunosuppressants. Clearance of these antibodies, including use, disease type, albumin concentration, and degree of systemic inflammation Furthermore, for many of these drugs, as distinct from drug dose, Consistency between efficacy and exposure, such that higher trough drug concentrations are associated with higher efficacy Differences in drug clearance may be an important explanation for this observation. Therefore, a better understanding of the clearance determinants of therapeutic antibodies is essential for optimal drug regimens. This may result in optimization.
[0057] In a previous study, we investigated the pharmacokinetics and pharmacodynamics of a single dose of vedolizumab (α4β7 receptor The efficacy, safety, and tolerability of 0.2 to 10 mg / kg of (intravenous [IV] infusion) was studied over a range of doses (data not shown). After reaching this level, vedolizumab serum concentrations generally remained constant until concentrations reached approximately 1–10 ng / mL. The concentrations then appeared to decrease in a nonlinear manner. Multiple-dose pharmacokinetics and pharmacodynamics of dolizumab in patients with CD showed a 0.5 After IV infusion of ~2mg / kg and in patients with UC, injections of 2, 6, and 10mg / kg were administered. The efficacy and safety of UC in patients with UC was investigated after administration of 2 to 10 mg / kg of Following IV infusion, the pharmacokinetics of vedolizumab was generally linear. Near-complete α4β7 receptor saturation was achieved after the initial dose of vedolizumab.
[0058] The efficacy and safety of vedolizumab induction and maintenance therapy were evaluated in the GEMINI2 (Clinica lTrials.gov number NCT00783692 and GEMINI3 (Clini In a randomized controlled trial (calTrials.gov number NCT01224171), The exposure of vedolizumab to induction and maintenance therapy in patients with CD was demonstrated in Response (efficacy) relationships are presented elsewhere.
[0059] As used herein, a fistula(s) refers to one fistula and / or two or more fistulas. Refers to...
[0060] Treatment of fistulizing Crohn's disease with anti-α4β7 antibody In one aspect, the present invention provides a method for treating fistulizing Crohn's disease in a human patient, comprising administering to the patient a therapeutically effective amount of stimulants to the fistulizing tissue (e.g., splenic tissue, pulmonary artery, pulmonary artery, pulmonary stenosis, pulmonary artery, pulmonary ... stools), e.g., draining perianal fistula(s) and / or elsewhere, e.g., the abdominal cavity or an anti-α4β7 antibody described herein in an amount effective to treat an enterocutaneous fistula(s). The human patient may be an adult (e.g., 18 years of age or older), The patient may be an adolescent or a child. A pharmaceutical composition comprising an anti-α4β7 antibody is useful for treating cloaca with fistulas. The compounds can be used as described herein to treat Crohn's disease in a subject suffering from the disease. The fistula(s) were removed 2 weeks, 4 weeks, 6 weeks, and 2 months prior to treatment with an α4β7 antagonist. , 3 months, 4 months, 6 months, 3-6 months, 2-4 months, or 3-7 months Prior to treatment with an α4β7 antagonist, e.g., an anti-α4β7 antibody such as vedolizumab, human Patients must have had a surgically implanted drainage line at the site of the fistula(s). The drainage line was removed approximately 1 week, 2 weeks, 3 weeks, 4 weeks, and 5 weeks before administration of the anti-α4β7 antibody. The drain may be surgically placed for approximately 1 week, or approximately 6 weeks. Drains surgically placed prior to administration of the anti-α4β7 antibody may be removed during treatment. For example, the drainage line may be removed at or after the 10th week, at or after the 14th week, at or after the 22nd week, The drainage line may be removed at or after the 22nd week or between the 22nd and 30th week. (several) may be removed any time after a significant reduction in drainage is observed.
[0061] Drainage is a surgical procedure used to assist in the healing of the fistula(s). The procedure involves inserting a surgical grade cord into the stoma to create a loop where the cord connects to the outside of the stoma. The cord is inserted into the fistula tract so that the outside of the wound can close, rather than being blocked. Provides a continuous drainage path for the fistula while it heals. Keeps the fistula tract open. This can help prevent pus or other infectious material from being trapped in the wound. , tight or closed, depending on the anatomical location of the fistula(s) and what may be medically required. They may be tied loosely and with a variety of materials. Drains are used to prevent sepsis and painful exacerbations. As a symptomatic treatment or prior to surgical resection, such as in fistulotomy or fistulectomy May be tied loosely as a temporary measure. In some types of fistula(s), a drainage line may be used. The drainage loop may be tied at a higher tension and periodically tightened. In this case, the drainage loop is surgically Instead, the loop essentially "pulls" the tissue out of the fistula, leaving a scar behind. Patients may be treated with immunomodulatory agents, TNFα antagonists, or a combination of both. Lack of adequate response to combination therapy, loss of response to said therapy Patients may have had a history of refractory or intolerant disease for their underlying CD. Lack of adequate response to either conventional therapy or tumor necrosis factor alpha (TNFα) antagonists have had or lost response to it, or have been intolerant to it Patients may have had at least one prior stenosis for fistulizing Crohn's disease. Patients may have been treated with corticosteroids (e.g., prednisone). had an inadequate response to or was intolerant to corticosteroids Patients may have been tolerant or dependent on corticosteroids. An inadequate response to corticosteroids was 30 mg orally daily for 2 weeks or intravenously for 1 week. History of at least one 4-week induction regimen containing 1 g of prednisone equivalent Refers to the signs and symptoms of persistently active disease, regardless of the severity of the disease. Loss of response was defined as a reduction in corticosteroids to less than the equivalent of 10 mg oral prednisone daily. Corticosteroid intolerance refers to two failed attempts to reduce the History of Schling syndrome, osteopenia / osteoporosis, hyperglycemia, insomnia and / or infections Examples include:
[0062] Immunomodulatory agents include, for example, oral azathioprine, 6-mercaptopurine, or methotrexate. An inadequate response to an immunomodulatory agent is defined as at least one 8-week course of regimen or oral azathioprine (≥ 1.5 mg / kg), 6-mercaptopurine ( ≥ 0.75 mg / kg), or methotrexate (≥ 12.5 mg / kg) Refers to signs and symptoms of persistently active disease, regardless of the severity of the disease. These include, but are not limited to, nausea / vomiting, abdominal pain, pancreatitis, abnormal liver function tests (LFTs), and liver dysfunction. Lymphopenia, thiopurine methyltransferase (TPMT) gene mutations and / or Infectious diseases are included.
[0063] In one embodiment, the patient is diagnosed with a lack of adequate response to treatment with a TNFα antagonist, Patients may have had a loss of response to TNFα antagonism or may have been intolerant to the treatment. The drug may be, for example, an agent that inhibits the biological activity of TNFα, and preferably binds to TNFα, e.g. Monoclonal antibodies, e.g., REMICADE (infliximab), HUMIRA (adalimumab), CIMZIA (certolizumab pegol), SIMPONI (golimumab or circulating receptor fusion proteins, such as ENBREL (etanercept). An inadequate response to TNFα antagonists was defined as at least one 4-week course of infliximab 5 mg / kg IV, 2 doses at least 2 weeks apart as an induction regimen; one 40 mg dose at least 2 weeks apart following subcutaneous administration of adalimumab; or 0 mg subcutaneous certolizumab pegol followed by 2 doses at least 2 weeks apart Refers to signs and symptoms of persistently active disease, regardless of disease progression. Response to TNFα antagonists Loss of efficacy refers to the recurrence of symptoms during maintenance treatment after previous clinical benefit. Adverse reactions include, but are not limited to, infusion-related reactions, demyelination, congestive heart failure, and / or or an infection.
[0064] Treatment is fistula healing in patients with moderately active to severely active Crohn's disease. As used herein, "moderately active to severely active clonogenic "Crohn's disease" refers to Crohn's disease with a CDAI score in the range of 220 to 400. In embodiments, the treatment comprises administering to a patient a blood glucose level of less than 330, 220-350, or 220-330 prior to treatment. This may result in fistula healing in patients with a CDAI score. In some embodiments, the treatment includes: It may result in fistula healing in patients with severely active Crohn's disease. In this case, the treatment is performed at 330, 330-400, 350-450 or 330-450 before treatment. In some embodiments, the method may result in fistula healing in patients with a CDAI score greater than 0. Treatment is for >350, >400, >425, or >375-500 or >400 This may result in fistula healing in patients with CDAI scores in the range of 600. or surgery to remove fistula-containing tissue, such as a fistulectomy or fistulotomy. or other surgical procedures for Crohn's disease, such as strictureplasty, resection, colectomy or colonoscopy. This can prevent the need for bowel resection. With regard to Crohn's disease, "fistula healing" refers to the closing of fistulas (complex In some embodiments, the healed fistula(s) results in closure or elimination of the fistula(s). The fistula was closed and no longer drained despite light digital pressure. Healing of the fistula was confirmed by magnetic resonance imaging (MRI). MRI), for example, pelvic MRI. he Simple or complex fistula(s) for scoring using MRI scores (also meets the Parks criteria for classification as intersphincteric, transsphincteric, suprasphincteric, or extrasphincteric Classify the patient's fistula(s) by and / or reduction in T2 hyperintensity from baseline Healing of the fistula(s) can be measured by contrast enhancement using MRI. Based on the weighted images, the change in the inflammatory process from baseline can be evaluated. an Assche is a method for the assessment of disease severity in patients with CD with perianal fistulas. This scoring method is an MRI-based scoring system that uses an overall score of 0 to 24. Six components summarized in the core (number, location, extension, hyperintensity on T2-weighted images, This objective scoring method is used to assess response to therapy. It can be evaluated by examining T1- and T2-weighted images of the perianal area (pelvic MRI). The fistula(s) can be classified and the overall extent of perianal disease assessed. Based on the contrast images, local inflammatory activity can be assessed. T2 images of the lesions as grade 1 showed active fistula(s) and abscesses with active inflammatory processes. The normal anal area containing the fistula tract is visible and the scar tissue appears hypointense. and comparing the computed T2 signal intensity values with the T2 signal intensity of healthy tissue (e.g., muscle or fat). The relative mean T2 signal intensity change can be evaluated by After contrast enhancement, T1-weighted imaging can be performed. The contrast-enhanced T1-weighted image can be compared with the baseline image. In some embodiments, the treatment can be compared to the image to assess response to therapy. This could result in fistula healing as measured by a reduction in T2 hyperintensity from baseline. Post-contrast T1-weighted images can be used to assess changes in the inflammatory process from baseline. can be done.
[0065] Treatment was at the start of treatment (day 1) compared with weeks 2, 6, 10, 14, 22, and 30. The Perianal Disease Activity Index (PDA) The Crohn's Disease Activity Index (PDAI) and / or the Crohn's Disease Activity Index (CDAI) were used to assess The PDAI can result in improvements in clinical disease activity, which is measured by the following five categories: Includes: types of disease involving discharge, pain, limitation of sexual activity, fistulas, e.g. perianal disease The severity of the disease and induration. Each category ranges from no symptoms (score 0) to severe symptoms (score 4). PDAI scores are rated on a 5-point scale ranging from 0 to 20. Higher scores indicate more severe disease. In some embodiments, at or 6 weeks after treatment, PDAI scores at 0, 14, or 22 weeks were at least 3% higher than baseline points, at least 6 points from baseline, at least 8 points from baseline, At least 10 points or 2-10 points, 3-12 points, 1-8 points, 0-6 points or 0- The range of reduction may be up to 4 points after treatment or at 6, 10, 14 or 2 weeks of treatment. 2-week CDAI scores: <200, <190, <180, <170 , less than 160 points, less than 150 points, or 100-200 points, 175-125 points, 175- The range of scores may be 75, 150 or 0. A CDAI score of less than 150 is considered remission. can be.
[0066] In some embodiments, fistula healing occurs within about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, or about 20 days after the initial treatment. After about 12 weeks, about 14 weeks, about 15 weeks, about 20 weeks, about 22 weeks, and about 30 weeks In some embodiments, the effect is seen about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks after the first treatment. Within 1 to 3 weeks of the initial dose of α4β7 antagonist, or within 2 to 4 weeks The initial fistula closes within 3 to 5 weeks, or within 3 to 7 weeks. may be a fistula healing event, such as about 30%, about 35%, about 40%, about 40%, or about 50% of the patient's fistula(s) healing. 5%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 8 5%, about 90%, or about 95% have been healed. In some embodiments, partial fistula healing is , about 4 weeks, about 5 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks after the first treatment or within 3 to 5 weeks, 3 to 7 weeks, or within about 14 weeks of the initial dose of α4β7 antagonist Within 12 weeks, within 6 to 22 weeks, within 8 to 14 weeks, or within 10 to 22 weeks. In one embodiment, 100% of the fistula(s) present at the time of treatment initiation were healed. A decrease in the number of stools (stomach sacs) is measured by using light finger pressure on the patient to assess whether drainage occurs. Observable based on a physician's physical evaluation. In some embodiments, the number of fistula(s) is decreased by 1. In other embodiments, the number of fistula(s) is decreased by 2, 3, or 4. This reduction occurred between 4 and 8 weeks, 6 and 10 weeks, 8 and 12 weeks, or 6 and 14 weeks of treatment. 100% fistula(s) closure is defined herein as meaning that all fistula(s) are mildly It is defined as no more drainage despite finger pressure. In some embodiments, % of fistulas(s) were detected 6–14 weeks, 8–16 weeks, and 10–20 weeks after the initial dose of α4β7 antagonist. Closed by ~20 weeks, 14-22 weeks, 20-30 weeks, or 12-30 weeks. In one embodiment, 100% of the fistula(s) are cleared by 30 weeks after the initial dose of the α4β7 antagonist. In some embodiments, the α4β7 antagonist is vedolizumab. In embodiments, α4β7 antagonist treatment is effective in 20% to 40% of patients, 30% to 50% of patients, 20% to 50% of patients, 5%–60% of patients, 35%–70% of patients, at least 50% of patients, at least 65 % of patients, resulting in 100% closure of the fistula(s) in at least 75% of patients In some embodiments, 2-6 doses of an α4β7 antagonist in addition to pre-α4β7 antagonist drainage placement. Antidote treatment resulted in 100% fistula(s) closure and drain clearance by 30 weeks of treatment vinegar.
[0067] In some aspects, the treatment results in a reduction in the number of pads used for fistula(e) drainage. The number of pads used daily by patients for fistula(e) drainage is about 10%, about 20% , about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% The patient may no longer require fistula(e) drainage pads following treatment with the anti-α4β7 antibody. This reduction can be achieved within 3 weeks after the first treatment with anti-α4β7 antibodies. By 4 weeks, By 6 weeks, By 8 weeks, By 10 weeks, By 12 weeks may occur within 3-6 weeks, 4-8 weeks, 6-10 weeks, or 8-14 weeks. do.
[0068] In some embodiments, after fistula(s) closure, e.g., after 4 to 8 doses of an α4β7 antagonist, Treatment with a 4β7 antagonist or continued treatment with the antagonist may maintain closure of the fistula(s). or prevent the development of new fistula(s) or draining fistula(s). In some embodiments, the maintenance of closure of the fistula(s) has a duration of at least 3 months. For example, fistula(s) closure was maintained for 3-6 months, 4-9 months, 6-12 months, or 9-16 months. In some embodiments, the inventive step is performed for 12 to 18 months, 16 to 24 months, or 30 months or more. Duration of fistula(s) closure was ≥6 months, ≥9 months, ≥12 months, ≥16 months, In some embodiments, the fistula(s) are closed. Maintenance of the chain comprises continued treatment with an α4β7 antagonist. Maintenance of the chain comprises treatment with an anti-α4β7 antibody. The anti-α4β7 antibody administered during chain maintenance is vedolizumab. Dolizumab is used in maintaining closure of the fistula(s). In this embodiment, dolizumab is administered every 2 weeks. once every 4 weeks, once every 8 weeks, once every 10 weeks or once every 12 weeks Dolizumab may be administered.
[0069] Treatment may also involve the reduction, elimination, or reduction and elimination of corticosteroid use by the patient. It can be achieved.
[0070] The preparation of α4β7 antagonists, such as anti-α4β7 antibodies, inhibits the activity of the α4β7 integrin and its ligands. For therapeutic purposes, an effective amount is administered to inhibit binding to the desired treatment (prophylaxis). would be sufficient to achieve the desired effect (e.g., reducing the number of draining fistula(s) (an amount sufficient to inhibit and / or eliminate the α4β7 antibody) Saturation of the integrin, i.e., effective titer sufficient to maintain neutralization, is required to ensure healing of the fistula(s). The formulations of the present invention can induce a clinical response or remission of Crohn's disease. Or multiple doses can be administered. The dosage can be determined by methods known in the art. and may depend, for example, on the age, sensitivity, tolerance, and overall well-being of the individual. Examples of modes of administration include topical routes, e.g., nasal or inhalation or transdermal administration, enteral routes, e.g. For example, via feeding tube or suppository, and parenteral routes, for example, intravenous, intramuscular, subcutaneous, intravenous, intravenous. Intravenous, intraperitoneal, or intravitreal administration is possible. A suitable dosage for the antibody is about 0.1 mg / mL per treatment. mg / kg (body weight) to about 10.0 mg / kg (body weight), for example, about 2 mg / kg to about 7 mg / kg, about 3 mg / kg to about 6 mg / kg, or about 3.5 mg / kg to about 5 mg / kg In certain embodiments, the dose administered may be about 0.3 mg / kg, about 0.5 mg / kg, or about 0.5 mg / kg. kg, approx. 1mg / kg, approx. 2mg / kg, approx. 3mg / kg, approx. 4mg / kg, approx. 5mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, or about 1 In some embodiments, the dose is 50 mg, 100 mg, 300 mg, 500 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 100 mg, 150 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, Vedolizumab is administered at a dose of 108 mg or 600 mg. g, 216mg, 160mg, 165mg, 155-180mg, 170mg or 18 Vedolizumab will be administered at a dose of 0 mg.
[0071] For antibody formulations stored as lyophilized solids, the antibody should be solubilized in a solution such as water for injection prior to administration. Reconstitute. When preparing for injection, dilute the reconstituted antibody (e.g., anti-α4β7 antibody) The final dosage form after administration (in saline, Ringer's solution, or 5% dextrose injection system) was The final dosage form may be about 1.0 mg / ml to about 5 mg / ml. ml ~ approx. 1.4mg / ml, approx. 1.0mg / ml ~ approx. 1.3mg / ml, approx. 1.0mg / ml ~ approx. 1.2mg / ml, approx. 1.0mg / ml ~ approx. 1.1mg / ml, approx. 1.1mg / ml ~ approx. 1.4 mg / ml, approx. 1.1 mg / ml ~ approx. 1.3 mg / ml, approx. 1.1 mg / ml ~ approx. 1.2mg / ml, approx. 1.2mg / ml ~ approx. 1.4mg / ml, approx. 1.2mg / 1.3 mg / ml to about 1.3 mg / ml, or about 1.3 mg / ml to about 1.4 mg / ml. The final dosage form may be about 0.6 mg / ml, about 0.8 mg / ml, about 1.0 mg, about 1.1mg / ml, approx. 1.2mg / ml, approx. 1.3mg / ml, approx. 1.4mg / ml, approx. 1.5mg / ml, about 1.6mg / ml, about 1.8mg / ml or about 2.0mg / ml In one embodiment, the total dose is 180 mg. In another embodiment, the total dose is The dose is 300 mg. A 300 mg dose of anti-α4β7 antibody is administered in 250 ml of water. It can be diluted in saline, Ringer's solution, or 5% dextrose solution.
[0072] In some embodiments, the dosing regimen has two phases: an induction phase and a maintenance phase. , for specific purposes such as induction of immune tolerance to antigens or induction of clinical responses and symptoms of Crohn's disease. The antibody is then rapidly administered to the subject in a manner that rapidly provides an effective amount of the antibody or antigen-binding fragment thereof suitable for recovery. The patient may be administered anti-α4β7 antibody when first being treated with the antibody, or may be administered anti-α More than 3 months, more than 4 months, more than 6 months, more than 9 months since 4β7 antibody treatment , treated after a long period of absence of treatment of greater than 1 year, greater than 18 months, or greater than 2 years reversal of fistulizing Crohn's disease symptoms during the maintenance phase of anti-α4β7 antibody therapy For example, if there is a relapse after disease remission, induction treatment can be administered. In some embodiments, the induction phase regimen comprises a mean steady-state trough that is maintained during the maintenance regimen. This results in a higher mean trough serum concentration, for example the concentration immediately prior to the next dose.
[0073] During the maintenance phase, the response achieved by induction therapy is maintained at a stable antibody level. A maintenance regimen is administered to treat relapse or complete closure of fistulizing Crohn's disease. A maintenance regimen can be, for example, a simple dosing regimen. Dimens can provide convenience to patients or require less frequent visits for treatment. In some embodiments, the maintenance regimen is low-dose, infrequent administration, self-administration, and The method of the present invention provides a method for the preparation of an anti-α4β7 antibody by a strategy selected from the group consisting of any combination of the above. For example, this can include administration in a formulation described herein.
[0074] In one embodiment, for example during the induction phase of treatment, the dosing regimen is An effective amount of anti-α4β7 antibody is provided in the formulations described herein to induce remission of the disease. In some embodiments, the effective amount of anti-α4β7 antibody is determined by administering to the patient a dose of anti-α4β7 antibody by the end of the induction phase. About 5 μg / ml to about 60 μg / ml, about 15 μg / ml to about 45 μg / ml, about 20 μ g / ml to about 30 μg / ml, or about 25 μg / ml to about 35 μg / ml The duration of the induction phase is about 4 weeks, about 5 weeks, or about The induction regimen may be for about 6 weeks, about 7 weeks, or about 8 weeks of treatment. The formulations described herein include, for example, high doses, frequent administration, and and a combination of high doses and frequent dosing. The induction dose may be one or more than one dose, e.g., at least two doses. During the induction phase, the dosage can be once daily, every other day, twice weekly, once ... It can be administered once every 0 days, once every 2 weeks, or once every 3 weeks. In one embodiment, an induction dose is administered within the first two weeks of treatment with the anti-α4β7 antibody. In this study, the induction dose was administered once at the start of treatment (day 0) and once approximately 2 weeks after the start of treatment. In another embodiment, the duration of the induction phase is 6 weeks. The duration of the phase is 6 weeks, with multiple induction doses administered during the first 2 weeks. In terms of form, the induction phase lasts for 10 weeks.
[0075] In some embodiments, for example, patients with severe Crohn's disease (e.g., those receiving anti-TNFα therapy) The induction phase is for patients with mild or moderate disease when starting treatment with rituximab (patients who have previously failed rituximab). In some embodiments, the patient may have a longer duration of disease than a patient with severe disease. The induction period for patients with In one embodiment, the treatment may have a duration of at least 12 weeks or at least 14 weeks. The dosing regimen for patients with idiopathic pulmonary disease is as follows: Week 0 (start of treatment) dose, Week 2 dose, and In another embodiment, the dosing regimen for patients with severe disease may include a dose at week 6. may include a dose at week 0 (start of treatment), a dose at week 2, a dose at week 6, and a dose at week 10. do.
[0076] In one embodiment, for example, during the maintenance phase of treatment, the dosing regimen comprises administering about 5 mg of anti-α4β7 antibody. ~about 40μg / mL, about 5 to about 25μg / mL, about 7 to about 20μg / mL, about 5 to about 10 μg / mL, about 10 to about 40 μg / mL, about 10 to about 20 μg / mL, about 15 to about 25 μ 5 μg / mL or about 9 to about 13 μg / mL mean steady-state trough serum concentration, e.g., In another embodiment, the dosing regimen maintains the plateau concentration immediately prior to administration, e.g. During the maintenance phase, about 15 to about 40 μg / mL, about 20 to about 30 μg / mL of anti-α4β7 antibody, About 20 to about 55 μg / mL, about 30 to about 45 μg / mL, about 45 to about 55 μg / mL or maintains a mean steady-state trough serum concentration of about 35 to about 40 μg / mL.
[0077] Dosages are once a week, once every 2 weeks, once every 3 weeks, once every 4 weeks, or once every 6 weeks. It can be administered once every 8 weeks, once every 10 weeks, or once every 12 weeks to induce remission of active disease. To guide or treat new patients, e.g., to demonstrate tolerance to anti-α4β7 antibodies For induction, higher or more frequent doses, e.g., once a week, every two weeks Dosages of once, once every three weeks, or once every four weeks may be useful. For example, to maintain remission in patients with chronic disease, less frequent doses, e.g. , once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 8 weeks or once every 10 weeks In one embodiment, a treatment regimen includes doses at day 0, about week 2, about week 6, and about week 7. week, at about week 10, and every 4 weeks or every 8 weeks thereafter. The maintenance regimen includes a dose every 8 weeks. Patients in the maintenance regimen of 1 dose every 8 weeks In embodiments where the patient experiences a return of disease symptoms, e.g., has a relapse, the frequency of administration may be increased. , for example, can be increased to once every four weeks.
[0078] The dose can be administered to the patient in about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, or about 40 minutes. It is.
[0079] Optimize dosing regimens to improve fistula(s) healing and clinical response in patients with Crohn's disease and induce clinical remission. does not alter the CD4:CD8 ratio in the cerebrospinal fluid of patients receiving
[0080] In some embodiments, durable clinical remission, e.g., complete recovery within 6 months or 1 year after initial treatment, is achieved. Clinical remission sustained through at least 2, at least 3, or at least 4 physician visits is achievable with optimized dosing regimens.
[0081] In some embodiments, a durable clinical response, e.g., at least one agonist, agonist, or antagonist, is observed for at least six months after initiation of treatment. Clinical responses lasting at least 9 months and at least 1 year can be achieved with optimized dosing regimens. be.
[0082] In one embodiment, the dosing regimen includes an initial dose of 300 mg, followed by 30 mg about two weeks after the initial dose. a second subsequent dose of 300 mg approximately 6 weeks after the initial dose, a third subsequent dose of 300 mg approximately 6 weeks after the initial dose, A fourth subsequent dose of 300 mg was administered approximately 10 weeks later, and a fifth dose of 300 mg was administered approximately 14 weeks after the initial dose. subsequent doses of 300 mg every 4 weeks or every 8 weeks after the 5th subsequent dose.
[0083] Vedolizumab can be administered once daily, weekly, monthly, or yearly. In some embodiments, at least one month after one or more doses of vedolizumab, Vedolizumab will be administered again at least once after at least 6 months or at least 1 year. In one embodiment, 300 mg of vedolizumab is administered at weeks 0, 2, and 6, followed by 4 weeks In some embodiments, 300 mg of vedolizumab may be administered intravenously every 24 hours or every 8 weeks. The drug was administered intravenously at weeks 0, 2, and 6, followed by administration at 2, 3, or 4 week intervals. Vedolizumab may be administered at 108 mg subcutaneously every 8 weeks.
[0084] In some embodiments, the treatment method, dose or administration regimen is provided when the patient is Reduces the likelihood of a human anti-human antibody (HAHA) reaction to the antibody. For example, when measured with antibodies reactive to anti-α4β7 antibodies, the clearance of anti-α4β7 antibodies is e.g., by increasing the serum concentration of anti-α4β7 antibodies, ... This reduces the number of anti-α4β7 antibodies bound to the integrin, thereby reducing the efficacy of the treatment. In some embodiments, patients are treated with an induction regimen followed by a maintenance regimen to prevent HAHA. In some embodiments, an intermediate period between the induction and maintenance regimens may be administered. In some embodiments, the induction regimen comprises administering multiple doses of an anti-α4β7 antibody to the patient. To prevent HAHA, high doses of anti-α4β7 antibody should be administered at the first treatment. Initial dose, e.g., at least 1.5 mg / kg, at least 2 mg / kg, at least 2.5mg / kg, at least 3mg / kg, at least 5mg / kg, at least 8mg g / kg, at least 10 mg / kg or about 2 to about 6 mg / kg, or multiple initial doses For example, patients should be administered a standard dose of about once a week, about once every two weeks, or about once every three weeks. In some embodiments, the treatment method can treat at least 30% of patients. , at least 40%, at least 50%, at least 60%, at least 70%, less maintain at least 80%, at least 90% or at least 95% as HAHA negative. In other embodiments, the treatment method is for at least 6 weeks, at least 10 weeks, at least 1 5 weeks, at least 6 months, at least 1 year, at least 2 years, or duration of treatment The patient is maintained as HAHA negative over a period of time. At least 30%, at least 40%, at least 50% or more of patients exhibiting HAHA At least 60% maintain low titers of anti-α4β7 antibodies, e.g., ≦125. The treatment method includes administering to the patient at least 12 weeks after the first treatment with an anti-α4β7 antibody. Maintain 70% of patients as HAHA negative.
[0085] The formulation of anti-α4β7 antibodies can be administered to an individual (e.g., a human) alone or in combination with another agent. The formulations of the present invention can be administered before, together with, or after the additional drug. In one embodiment, one or more of the following are provided that inhibit the binding of α4β7 integrin to its ligands: In this embodiment, the agent, e.g., a monoclonal antibody, e.g., Anti-MAdCAM (e.g., anti-MAdCAM1) or anti-VCAM1 monoclonal antibodies In another embodiment, the additional agent is administered to the leukocyte via a pathway other than the α4β7 pathway. Inhibits globulin binding to endothelial ligands. The agent is, for example, a chemokine (CC motif) Thymic expression of chemokines (TECK or CCL2) on CCR9-expressing lymphocytes 5) to agents that block binding of LFA1 to the intracellular adhesion molecule (ICAM) For example, in addition to the formulation of the present invention, anti-TECK or anti-C CCR9 antibodies or small molecule CCR9 inhibitors, e.g., those described in PCT Publication WO03 / 099773 or or an inhibitor disclosed in WO04 / 046092, or an anti-ICAM1 antibody or I In yet another embodiment, an oligonucleotide that blocks expression of the CAM is administered. Active ingredients (e.g., anti-inflammatory compounds, such as sulfasalazine, azathioprine, 6-mer Captopurine, a 5-aminosalicylic acid-containing anti-inflammatory drug, another nonsteroidal anti-inflammatory compound; Steroidal anti-inflammatory compounds or antibiotics commonly administered to control IBD (e.g. , ciprofloxacin, metronidazole), or another biologic agent (e.g., TNFα In some embodiments, anti-α4β7 An antibiotic is administered at the start of treatment with the antibody. In some embodiments, the antibiotic is metronidazole. In some embodiments, the anti-α4β7 antibody is Antibiotics are administered on day 1 of treatment. In a further embodiment, treatment with anti-α4β7 antibodies first 2 weeks, first 3 weeks, first 4 weeks, first 5 weeks, first 6 weeks or first In one embodiment, the dose of the co-administered drug is an anti-α4β7 antibody. The effect of anti-α4β7 antibody preparations can be reduced over time during treatment. Steroids (e.g., prednisone, Patients who are being treated with anti-α4β7 antibody therapy should be started as early as 6 weeks before treatment with anti-α4β7 antibody therapy. The patient will receive a tapering steroid regimen. Approximately 25% within 4 to 8 weeks of tapering, and approximately 8 to 12 weeks of tapering during treatment with anti-α4β7 antibody preparations In one embodiment, the anti-α4 By approximately 16-24 weeks of treatment with β7 antibody formulations, steroid doses can be eliminated. In another example, an anti-inflammatory drug may be administered at the start of or prior to treatment with an anti-α4β7 antibody formulation. Patients being treated with a compound, such as 6-mercaptopurine, may be given the above-mentioned steroid dose regimen. The patient will receive a tapering regimen as well as a regimen of reducing the dose of the anti-inflammatory compound.
[0086] In one embodiment, the method comprises administering to the patient an effective amount of a formulation of the invention. If the formulation is in a solid, e.g., dry, state, the administration process may include a step of converting the formulation into a liquid state. In one embodiment, for example, the method can include injection, e.g., intravenous, intramuscular, or subcutaneous injection. In another embodiment, the dry formulation can be reconstituted with the liquid described above for use in, for example, Solid or dry formulations may be administered topically in patches, creams, aerosols or suppositories. can.
[0087] The α4β7 antagonist, an anti-α4β7 antibody, targets an epitope on the α4 chain (e.g., humanized MAb b21.6 (Bendig et al., U.S. Patent No. 5,840,299), β7 chain The above epitopes (e.g., FIB504 or humanized derivatives (e.g., Fong et al. al., U.S. Patent No. 7,528,236), or by association of the α4 and β7 chains. It is capable of binding to the combinatorial epitopes formed. 4975, or other antibodies, are anti-α4β7 antibodies. This antibody binds to a combinatorial epitope on the α4β7 complex, but does not bind to the α4 chain or does not bind to epitopes on the β7 chain unless these chains are associated with each other. The association of tegrin and β7 integrin, for example, involves the binding of residues present on both chains together in close proximity. or by including the epitope of interest in one of the chains, e.g., the α4 integrin chain. or on the β7 integrin chain in the absence or presence of a suitable integrin partner. The three-dimensional structure of the epitope-binding site is inaccessible to antibody binding in the absence of integrin activation. By selectively exposing the peptides, combinatorial epitopes can be created. In one embodiment, the anti-α4β7 antibody binds to both the α4 and β7 integrin chains. and thus is specific to the α4β7 integrin complex. For example, α4β1 and / or α E In another embodiment, the anti-α The 4β7 antibody binds to the same or substantially the same epitope as the Act1 antibody (Laz arovits,AIet al.,J.Immunol.,133(4):185 7-1862(1984), Schweighoffer et al., J. Immu nol.,151(2):717-729,1993;Bednarczyk et a l., J. Biol. Chem., 269(11):8348-8354, 1994). The mouse ACT1 hybridoma cell line that produces mouse Act1 monoclonal antibody is On August 22, 2001, in accordance with the provisions of the Budapest Treaty, Millennium Pharmaceuticals,Inc.,40 Landsdowne St. et,Cambridge,Mass.02139,USA instead of America American Type Culture Collection, 10801 University Boulevard ,Manassas,Va.20110-2209,USA, under accession number PTA- In another embodiment, the anti-α4β7 antibody is disclosed in U.S. Pat. Human antibodies or α4β7 linkers using the CDRs provided in US Pat. No. 5,310,254,975. It is a synthetic protein.
[0088] In one embodiment, the α4β7 antagonist is an anti-MAdCAM antibody (see, e.g., U.S. Patent No. 8,277 See, for example, the antibodies described in PF-00547659 or WO2005 / 067620. ), or genetically engineered forms of the ligand, such as those described in U.S. Pat. No. 7,803,904. It is a MAdCAM-Fc chimera that
[0089] In one embodiment, the anti-α4β7 antibody is an antibody that binds to one or more of the ligands of α4β7 (e.g., mucosal adenocarcinoma). Resins, such as MAdCAM (e.g., MAdCAM1), fibronectin, and / or or vascular addressing receptor (VCAM). Primate MAdCAMs inhibit the binding of P No. 6,399,623, the entire teachings of which are incorporated herein by reference. In another embodiment, the anti-α4β7 antibody inhibits VCAM binding. MAdCAM (e.g., MAdCAM1) and / or fibronectin Inhibits binding to
[0090] In one embodiment, the anti-α4β7 antibody used in the treatment is a humanized version of the murine Act1 antibody. Suitable methods for preparing humanized antibodies are well known in the art. The antibody was synthesized by sequencing three heavy chain complementarity determining regions (CDRs, CDR1, SEQ ID NO: 4, CDR2, SEQ ID NO:5 and CDR3, SEQ ID NO:6) and an appropriate human heavy chain framework and the three light chain CDRs (CDR 1, SEQ ID NO:7, CDR2, SEQ ID NO:8 and CDR3, SEQ ID NO:9) and an appropriate human light chain The humanized Act1 antibody also contains a light chain containing the framework region. Any suitable human framework region, including the framework region, may be modified with amino acid substitutions. For example, one or more of the framework amino acids may be replaced with another. For example, the amino acid at the corresponding position in the mouse Act1 antibody can be substituted. The human constant region or portion thereof, if present, may be selected from the group consisting of human constant regions, including allelic variants. The κ or λ light chains of a human antibody, and / or the γ (e.g., γ1, γ2, γ3, γ4), μ, It can be derived from an α (e.g., α1, α2), δ or ε heavy chain. Tailoring effector functions Select a particular constant region (e.g., IgG1), variant or portion thereof, for For example, mutated constant regions (variants) can be incorporated into the fusion protein. , can minimize binding to Fc receptors and / or the ability to fix complement (e.g. For example, Winter et al.,GB2,209,757B;Morrison e t al., WO89 / 07142; Morgan et al., WO94 / 2935 1, Dec. 22, 1994). Humanized versions of the Act1 antibody are disclosed in PCT Publication No. WO99 Nos. 8 / 06248 and WO07 / 61679, the disclosures of which are incorporated herein by reference. The teachings of each of these are incorporated herein in their entirety. The method is described in Publication No. US2005 / 0095238, Publication No. US2005 / 009523 8, WO2012151248 and WO2012 / 151247 .
[0091] In one embodiment, the anti-α4β7 antibody is vedolizumab. Vedolizumab IV (MLN000 2. ENTYVIO (also known as KYNTELES (trademark)) is a It is a humanized antibody (Ig) G1mAb directed against lymphocyte integrin α4β7. β47 integrin is a mucosal addressin expressed on the endothelium of mesenteric lymph nodes and GI mucosa. GI mucosa and gut-associated lymphoma through adhesive interactions with cell adhesion molecule 1 (MAdCAM1) Vedolizumab mediates lymphocyte trafficking to the GALT tissue. and antagonizes its adhesion to MAdCAM1, and as such, intestinal homin Reduces migration of leukocytes into the GI mucosa.
[0092] In another embodiment, the humanized anti-α4β7 antibody used in the treatment comprises the amino acids 20-1 of SEQ ID NO:1. 40, and amino acids 20 to 131 of SEQ ID NO: 2 or amino acids 20 to 131 of SEQ ID NO: 3. Optionally, a suitable human constant region(s) may be included. For example, a humanized anti-α4β7 antibody may have a sequence similar to that of amino acids 20 to 470 of SEQ ID NO:1. and a light chain comprising amino acids 1 to 219 of SEQ ID NO:3. The humanized anti-α4β7 antibody has a heavy chain comprising amino acids 20 to 470 of SEQ ID NO:1 and a sequence Vedolizumab can include a light chain comprising amino acids 20 to 238 of number 2. Registration number 943609-66 under the Chemical Abstracts Service (CAS, American Chemical Society) It is classified as -3.
[0093] Substitutions into the humanized anti-α4β7 antibody sequence can include, for example, substitutions into the heavy and light chain framework regions. Mutations, such as an isoleucine to valine mutation at residue 2 of SEQ ID NO:10; Mutation of methionine to valine at residue 4 of SEQ ID NO:10; mutation of residue 24 of SEQ ID NO:11 an alanine to glycine mutation at residue 38 of SEQ ID NO:11; an arginine to lysine mutation at residue 38 of SEQ ID NO:11 Mutation of alanine to arginine at residue 40 of SEQ ID NO:11; methionine to isoleucine mutation at residue 8 of SEQ ID NO:11; Mutation of soleucine to leucine; arginine to valine for residue 71 of SEQ ID NO:11 a threonine to isoleucine mutation at residue 73 of SEQ ID NO:11; any combination thereof; and the CDRs (CD R1, SEQ ID NO:4, CDR2, SEQ ID NO:5 and CDR3, SEQ ID NO:6); and The light chain CDRs of the mouse Act1 antibody (CDR1, SEQ ID NO: 7; CDR2, SEQ ID NO: 8 and CDR3, SEQ ID NO:9).
[0094] In a first aspect, the present invention relates to a cloaca having a surgically placed drainage line and a fistula. The present invention provides a method of treating a patient suffering from IBD with vedolizumab. administering two doses of vedolizumab to a patient suffering from the disease, wherein an initial dose is administered to the patient. Approximately two weeks after the first dose, the patient is given a second dose, and then after waiting approximately four weeks, the patient's vedolizumab serum is and determining whether the patient has a serum concentration of at least about 8, about 10, about 12, about 14, about 17, about 20, about 25, about 30, about 35, or about 40 μg / ml, The method includes administering a dose of vedolizumab to a patient, the patient having a serum concentration of about 10 to 50, about 12-25, about 15-17, about 17-25, about 12-40, or about 17-40 μg / m The patient's serum concentration, e.g., trough serum concentration, may be greater than 17 μg / ml and less than 25 μg / ml. g / ml or greater than 35 μg / ml.
[0095] Separately, patients with fistulizing Crohn's disease were given at least one dose of Vedrin. Administer izumab and wait at least about 2 weeks, or optionally, 2 to 5 weeks, before administering and determining whether the patient has a serum concentration of at least about 8, about 10, about 12, or When the concentration is about 14, about 17, about 20, about 25, about 30, about 35, or about 40 μg / ml The patient may be administered one or more additional doses of vedolizumab at a time point of about 1 2-25, about 15-17, about 17-25, about 12-40, or about 17-40 μg / ml The patient's serum concentration, e.g., trough serum concentration, may be greater than 17 μg / ml, greater than 25 μg / ml, / ml, or greater than 35 μg / ml.
[0096] The present invention relates to a method for treating Crohn's disease with fistulizing ulcers, comprising administering to a patient a pulmonary bypass stenosis (PAS) treatment for Crohn's disease. The present invention provides an anti-α4β7 antibody for use in the treatment of patients who have undergone a cardiac transplant, Use is for at least 2 weeks after surgical implantation and at 2, 6, 10, 14, and 22 weeks thereafter. The patient is administered an anti-α4β7 antibody. For example, if you have been treated with an anti-TNF antibody and have experienced a recurrence of your fistula(s) after the treatment. Use may be during the early stages, e.g., on the first or second day of treatment with anti-α4β7 antibodies. Antibiotics were administered for 0-2 weeks, 0-4 weeks, 0-6 weeks, or 1-8 weeks. The use may include a period of 2 to 6 weeks, 4 to 10 weeks, or 6 to 10 weeks after the initial administration of the anti-α4β7 antibody. It may further include removal of the drainage line between 14 weeks, between 6 and 20 weeks, or between 14 and 30 weeks. Use is at 2, 4, 6, 8 or 10 days after 22 weeks for maintenance of healed fistula(s). In some embodiments, the method further comprises administering the anti-α4β7 antibody weekly. The 4β7 antibody is vedolizumab.
[0097] As used herein, "endoscopic remission" refers to a state of having a low endoscopic score. The endoscopic score in ulcerative colitis can be the Mayo subscore. An example of a method to assess the endoscopic score is ileocolonoscopy. The endoscopic score for Crohn's disease is the simple endoscopic score for Crohn's disease (S The SES-CD can be based on the size of the ulcer, the amount of ulcerated surface, and the extent of the affected surface. The amount of food consumed and whether and to what extent the digestive tract is narrowed It may include degrees.
[0098] As used herein, "endoscopic response" refers to the improvement in baseline endoscopic score (e.g., score This refers to the percentage decrease from the time of cleaning or immediately before the initial dose. Endoscopic response can be assessed by the Simple Endoscopic Score for Crohn's Disease (SES-CD).
[0099] In another reference to Crohn's disease, mucosal healing refers to the amount or severity of wounds in the mucosa, e.g., the digestive tract. Refers to an improvement in the severity, e.g., the amount, size, or severity of one or more ulcers in the digestive tract In another example, mucosal healing may refer to a reduction in wall thickness, bowel wall enhancement, mural edema, ulcers, etc. The term "intestinal hypervascularity" refers to a reduction in one or more parameters selected from the group consisting of intestinal hyperplasia, periintestinal vascularization, and intestinal hypervascularity. The mucosal healing was evaluated using the SES-CD score or the Magnetic Resonance Index of Activity (MAGNETIC RESONANCE INDEX). MaRIA score Complete mucosal healing in Crohn's disease is the absence of ulceration.
[0100] The "MaRIA score" may be calculated, for example, for each segment of the colon and terminal ileum (e.g., ileum, Various mucosal healing parameters for the ascending colon, transverse colon, descending colon, sigmoid colon, and rectum were score as measured by magnetic resonance enterography is the sum of.
[0101] As used herein, "corticosteroid (CS)-free remission" refers to oral Patients taking corticosteroids who discontinue corticosteroid use Patients with refractory disease and in clinical remission for 52 weeks.
[0102] As used herein, the European Quality of Life (European Quality of Life Life-5 Dimension (EQ-5D) Visual Analog Scale (VAS) ) is used to measure a patient's general health-related quality of life (HRQOL). Valid (ahrq.gov / rice / eq5dproj.htm, "USV aluation of the EuroQol EQ-5D(trademark)Health States" (accessed August 8, 2012), Bastida et al. BMC Gastroenterology 10:26-(2010), Konig et al. al.European Journal of Gastroenterology& Hepatology 14:1205-1215 ((2002)) It consists of five domains: mobility, self-care, daily activities, pain / discomfort, and anxiety / depression. Patients were asked to rate the level of their current health problems for each item as "none" or " Select "moderate," "severe," or "extreme" and score 1, 2, or 3, respectively. From these scores, a composite EQ-5D score can be calculated to calculate overall HRQOL. EQ-5D visual analogue scale (VAS) scores are measured on a 20 cm visual vertical axis. It is a self-assessment rating system that uses a scale of 0 to 1, with zero being the lowest possible health score and The EQ-5D and EQ-5D VAS are used to evaluate the HRQ of patients with GI disorders. Many studies have shown that EQ is a valid and reliable tool for measuring OL. A reduction of ≥ 0.3 points in the -5D score represents a clinically meaningful improvement in HRQOL for patients. An increase of 7 or more points in the EQ-5D VAS score represents an improvement in HRQOL for patients. represents a clinically meaningful improvement in
[0103] The Inflammatory Bowel Disease Questionnaire (IBDQ) (Irvine Journal of Clinical Oncology) f Pediatric Gastroenterology&Nutrition 2 8:S23-27(1999)) was used to evaluate the efficacy and safety of inflammatory bowel disease, ulcerative colitis, or cholecystectomy. The study assessed the quality of life of adult patients with chronic kidney disease by assessing the following four areas of HRQOL: The 32 questions included: enteral system (10 questions), emotional functioning (12 questions), social functioning ( Patients were asked to report on their symptoms and quality of life since the last 2 weeks. They were asked to recall their experiences and rate them based on a 7-point Likert scale (higher scores indicate better quality of life). Ask participants to rate each item by adding up the scores from each domain. Calculate the BDQ score. The total IBDQ score ranges from 32 to 224. A high IBDQ total score is characteristic of health-related quality of life (HRQoL) in patients in remission. It is a sign.
[0104] As used herein, "induction therapy" refers to the initial stage of treatment, during which the patient is first administered a therapeutic agent. Therapeutic agents, such as antibodies, can induce immune tolerance to the agent. or to induce a clinical response and ameliorate disease symptoms. The drug is administered in a manner that rapidly provides an effective amount of the drug suitable for the (See WO2012 / 151247 and WO2012 / 151248).
[0105] As used herein, "maintenance therapy" refers to therapy following induction therapy and is intended to provide The response achieved by the antibody is maintained at a steady level by administering a therapeutic agent, e.g., an antibody. Maintenance regimens can prevent the return of symptoms or recurrence of diseases such as IBD. (WO2012 / 151247 and WO201 Maintenance regimens can provide convenience to patients, e.g. A pure dosing regimen or infrequent clinic visits are required for treatment.
[0106] The present invention will be more fully understood by reference to the following examples. The examples should not be construed as limiting the scope of the invention. All literature and patent citations are incorporated herein by reference. , which is incorporated herein by reference. EXAMPLES
[0107] Example 1 This post-hoc exploratory analysis included patients with fistulizing disease at baseline in the GEMINI2 trial. The efficacy of vedolizumab was evaluated in a subpopulation of patients with glaucoma (NCT00783692). This is a phase 3 randomized, double-blind, PBO-controlled study consisting of separate induction and maintenance studies. In this study, 37% of patients had a history of fistulizing disease and 15% had active draining fistula(s) at baseline (week 0).
[0108] In GEMINI 2, 461 Patients achieved clinical responses and were randomized to placebo or vedolizumab 300 mg every 4 or 8 weeks. mg maintenance treatment (intention to treat [ITT] population). Closure of the fistula(s), the primary endpoint, was assessed at each visit (2-6 week intervals) through week 52. The number of patients who achieved fistula(e) closure and the mean time to fistula(e) closure were calculated.
[0109] At the start of the maintenance phase, 57 (12%) patients (N=461) in the ITT population had baseline had ≥1 draining fistula(s), and 79% of the fistula(s) were located in the perianal region. Among these patients, 44%–49% had failed prior anti-TNF therapy and 39%–54% Underwent prior surgery for CD. Received vedolizumab / placebo by week 14. Fistula(s) closure occurred in 28% of patients treated with vedolizumab compared with 11.1% of patients This difference was maintained through week 52. The Kaplan-Meier probability of (several) was 29.2% and 33% at 6 and 12 months, respectively. The hazard of fistula(s) closure in the VDZ / VDZ treatment group was 0.4% (Figure 2). The ratio was 2.54 (95% confidence interval [CI], 0.54-11.96).
[0110] These preliminary findings support a role for vedolizumab in the treatment of fistulizing disease. Further exploration of population-specific prospective studies is warranted.
[0111] [Table 1]
[0112] Example 2: Most patients in GEMINI2 (approximately 88%) had drainage when they enrolled in the study. Among these patients, 29 of the VDZ / PBO-treated patients had no pulmonary fistula(s). % and 21% of VDZ / VDZ-treated patients had a history of fistulizing disease. Over the course of the study, 3.2% of patients with CD developed a draining fistula(s). Patients who developed a hole(s) were more likely to develop a draining fistula(s) than those who did not. were more likely to have a history of fistulizing disease. The median was 16 weeks (range 4-36) in VDZ / PBO-treated patients and 16 weeks (range 4-36) in VDZ / VD In patients treated with VDZ, it was 6 weeks (range 4-42). The Kaplan-Meier probabilities of occurrence were 3.0% and 3.2% at 6 and 12 months, respectively. and 3.7% in VDZ / PBO-treated patients, and 3.1% and 4.8%, respectively. Hazard ratio for the development of draining fistula(s) during the study according to VDZ / VDZ treatment The CI was 0.77 (95% CI, 0.25, 2.43). VDZ / VDZ-treated patients who developed draining fistula(s) were more likely to develop draining fistula(s) than those who did not. A high percentage of patients had a history of anti-TNF failure (88%) and prior surgery for CD (75%). and had a higher median C-reactive protein (19.2 mg / L) but had a higher draining fistula ( In patients who did not develop any pulmonary embolism, 51%, 35%, and 8.8%, respectively, and VDZ No similar differences were observed in PBO-treated patients.
[0113] Example 3: A phase 4 randomized, double-blind, multicenter study was conducted to evaluate the efficacy and safety of 100 mg / kg / day in patients with active Crohn's disease (CD). The efficacy of 30 weeks of treatment (ending at 22 weeks) in healing of draining perianal fistula(s) in elephants A two-dose regimen of vedolizumab IV3 administered as a 30-minute infusion over a 30-minute period Patients in both treatment arms participating in this study will undergo care prior to enrollment in the study. The criteria were surgical drainage. Approximately 126 CD patients with 1-3 draining perianal fistula(s) of 2-week duration Subjects are included who are historically eligible for conventional or alternative therapy for their underlying CD. have had an inadequate response to either tumor necrosis factor alpha (TNFα) antagonists, or have lost response to or been intolerant to it Subjects will be randomized in a 1:1 ratio to one of two treatment arms: Arm 1: vedolizumab IV 300 mg dose at weeks 0, 2, 6, 14, and 22 and 10 weeks Placebo IV dose in eyes Arm 2: vedolizumab IV 300 mg dose at weeks 0, 2, 6, 10, 14, and 22
[0114] The study included a 3-week screening period, a 30-week treatment period (last dose at week 22). The study consisted of a 18-week follow-up period after the last dose. The duration of the study until post-treatment will be approximately 43 weeks for all subjects.
[0115] In both groups, provided there was a significant reduction in fistula(e) drainage and at the investigator's discretion, Drains may be removed after 10 weeks. It is advisable to remove all drains by 14 weeks. and must be removed by the 22nd week.
[0116] The primary objective of this study was to evaluate the efficacy and safety of vedolizumab IV 300m in subjects with fistulizing CD. To determine the proportion of subjects with healed fistula(s) at week 30 in two different dose regimens of g The incidence of fistulas at 30 weeks was significantly higher than that at baseline by magnetic resonance imaging (MRI). (Multiple options) Determine cure. From day 1 through weeks 2, 6, 10, 14, 22, and 30. Perianal Disease Activity Index (PDAI) and Crohn's Disease Activity Index (CDAI) were used to assess clinical outcomes. To assess clinical disease activity, perianal pain, and inflammation at 14 and 30 weeks. Quality of Life including Intestinal Bowel Disease Questionnaire (IBDQ) and EuroQol-5 Dimensions (EQ-5D) Compare quality measures to Day 1. Compare number of pads used at Week 30 to baseline. Evaluate the fistula(s) drainage by
[0117] The primary endpoint of the study was a reduction in the number of draining fistula(s) from day 1 to week 30. The proportion of subjects whose fistula(s) were closed was reduced by at least 50% (the proportion of subjects whose fistula(s) were closed was reduced by light acupressure). The secondary endpoint of this study was 100% at 30 weeks. The proportion of subjects whose fistula(s) were closed (all fistula(s) were closed with light finger pressure) time to first fistula closure; time to last (100%) fistula closure and duration of fistula(s) reaction (e.g., number of days with drainage). Time to first fistula closure and time to final fistula closure will be analyzed by survival analysis procedures.
[0118] [Table 2]
[0119] [Table 3]
[0120] [Table 4]
[0121] [Table 5]
[0122]
Table 6
[0123]
Table 7
[0124]
Table 8
[0125]
Table 9
[0126]
Table 10
[0127]
Table 11
Claims
1. 1. A method for treating a human patient suffering from fistulizing Crohn's disease, comprising the steps of: Patients with fistulizing Crohn's disease were treated with a 5-HT1 gene that specifically binds to the human α4β7 integrin. The isotopic humanized antibody was administered in the following dosing regimen: a. an initial dose of 300 mg of the humanized antibody as an intravenous infusion; b. followed by a second subsequent dose of 300 mg of said human ovarian hypertension administered as an intravenous infusion approximately two weeks after said initial dose. antibody; c. followed by a third subsequent dose of 300 mg of said human ovarian hypertension administered as an intravenous infusion approximately six weeks after said initial dose. antibody; d. followed by a fourth subsequent dose of 300 mg of said compound administered as an intravenous infusion approximately 10 weeks after said initial dose. Humanized antibodies; e. followed by a fifth subsequent dose of 300 mg of said compound administered as an intravenous infusion about 14 weeks after said initial dose. Humanized antibodies; f. followed by an intravenous infusion every 8 weeks after said fifth subsequent dose of said humanized antibody as needed. and a sixth subsequent dose and subsequent doses of 300 mg of the humanized antibody. and administering the compound according to the formula: the human patient has a drainage line surgically placed prior to administration of the antibody; The administration regimen induces fistula(e) healing; and Furthermore, the humanized antibody may comprise an antigen-binding region of non-human origin and at least one of the antigen-binding regions of an antibody of human origin. and a humanized antibody having binding specificity for the α4β7 complex. The original binding region comprises the following CDRs: Light chain: CDR1 SEQ ID NO:7 CDR2 SEQ ID NO:8 and CDR3 SEQ ID NO:9; and Heavy chain: CDR1 SEQ ID NO:4 CDR2 SEQ ID NO:5 and CDR3 SEQ ID NO:6 The method comprising:
2. The method of claim 1 , wherein the fistula is one or more draining fistulas.
3. 3. The method of claim 1 or 2, wherein the fistula(s) is / are one or more perianal fistula(s). The method according to
4. The fistula(s) healing was assessed by magnetic resonance imaging of fistula(s) healing at 30 weeks ( The method according to any one of claims 1 to 3, wherein the MRI evaluation is performed.
5. 3. The method of claim 2, wherein at least 50% of the draining fistulas are closed.
6. said at least 50% of draining fistulas remain draining for up to 14 weeks after said initial dose of said humanized antibody. The method of claim 5 , wherein the sealing member is closed at
7. 3. The method of claim 2, wherein 100% of the draining fistula(s) are closed.
8. The patient is receiving at least one of an immunomodulatory agent, a tumor necrosis factor alpha antagonist, or a combination thereof. Lack of adequate response to, or loss of response to, treatment with The method according to any one of claims 1 to 4, wherein the patient has a history of rheumatoid arthritis or has been intolerant to the same.
9. The method according to claim 1, wherein the Crohn's disease is moderately active to severely active Crohn's disease.
5. The method according to any one of claims 4 to 4.
10. The administration regimen reduces, eliminates, or reduces and eliminates drainage pad use by the patient. The method according to any one of claims 1 to 4,
11. 5. The method according to claim 1, wherein the humanized antibody is administered to the patient in about 30 minutes. The method described.
12. The humanized antibody according to any one of claims 1 to 4, wherein the humanized antibody is reconstituted from a lyophilized formulation. Method of posting.
13. The method of claim 12, further comprising reconstituting the humanized antibody into a stable liquid formulation.
14. The patient has a lack of adequate response to corticosteroids or The method according to any one of claims 1 to 4, characterized in that the loss of reaction
15. The immunomodulatory agent is azathioprine, 6-mercaptopurine, or methotrexate. The method according to claim 8, wherein
16. The treatment is measured by the patient's PDAI score or CDAI score. The method according to any one of claims 1 to 4.
17. 2. The patient's PDAI score is reduced by at least 3 points from baseline.
16. The method according to claim 16.
18. The humanized antibody has a heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:
1.
10. A method according to any one of the preceding claims.
19. the humanized antibody has a light chain variable region sequence of amino acids 20-131 of SEQ ID NO:2; 10. A method according to any one of the preceding claims.
20. The humanized antibody has a heavy chain comprising amino acids 20 to 470 of SEQ ID NO:1 and an amino acid sequence comprising SEQ ID NO:
2. The method of claim 18 or 19, having a light chain comprising amino acids 20 to 238.
21. 2. The method of any one of the preceding claims, wherein the humanized antibody is vedolizumab.
22. 1. A method for treating a human patient suffering from fistulizing Crohn's disease, comprising the steps of: Patients with fistulizing Crohn's disease were treated with a 5-HT1 gene that specifically binds to the human α4β7 integrin. The isotopic humanized antibody was administered in the following dosing regimen: a. an initial dose of 300 mg of the humanized antibody as an intravenous infusion; b. followed by a second subsequent dose of 300 mg of said human ovarian hypertension administered as an intravenous infusion approximately two weeks after said initial dose. antibody; c. followed by a third subsequent dose of 300 mg of said human ovarian hypertension administered as an intravenous infusion approximately six weeks after said initial dose. antibody; d. followed by a fourth subsequent dose of 300 mg of said compound administered as an intravenous infusion about 14 weeks after said initial dose. Humanized antibodies; e. followed by a fifth subsequent dose of said humanized antibody every eight weeks as an intravenous infusion as needed. 5 subsequent doses and subsequent doses of 300 mg of the humanized antibody and administering the compound according to the formula: the human patient has a drainage line surgically placed prior to administration of the antibody; said administration regimen induces fistula(e) healing; and Furthermore, the humanized antibody may comprise an antigen-binding region of non-human origin and at least one of the antigen-binding regions of an antibody of human origin. and a humanized antibody having binding specificity for the α4β7 complex. The original binding region comprises the following CDRs: Light chain: CDR1 SEQ ID NO:7 CDR2 SEQ ID NO:8 and CDR3 SEQ ID NO:9; and Heavy chain: CDR1 SEQ ID NO:4 CDR2 SEQ ID NO:5 and CDR3 SEQ ID NO:6 The method comprising:
23. 23. The method of claim 22, wherein the fistula(s) are one or more draining fistulas.
24. 24. The method of claim 22 or 23, wherein the fistula(s) is / are one or more perianal fistulas. How to.
25. The fistula(s) healing was assessed by magnetic resonance imaging of fistula(s) healing at 30 weeks ( The method according to any one of claims 22 to 24, wherein the MRI evaluation is performed.
26. 24. The method of claim 23, wherein at least 50% of the draining fistulas are closed.
27. said at least 50% of draining fistulas remain draining for up to 14 weeks after said initial dose of said humanized antibody.
27. The method of claim 26, wherein the sealing member is closed at
28. 24. The method of claim 23, wherein 100% of the draining fistulas are closed.
29. The patient is receiving at least one of an immunomodulatory agent, a tumor necrosis factor alpha antagonist, or a combination thereof. Lack of adequate response to, or loss of response to, treatment with The method according to any one of claims 22 to 25, wherein the patient has a history of rheumatoid arthritis or has been intolerant to the same.
30. The immunomodulatory agent is azathioprine, 6-mercaptopurine, or methotrexate.
30. The method of claim 29, wherein:
31. 22. The method of claim 21, wherein the Crohn's disease is moderately active to severely active Crohn's disease.
26. The method according to any one of claims 1 to 25.
32. The administration regimen reduces, eliminates, or reduces and eliminates drainage pad use by the patient. The method according to any one of claims 22 to 25,
33. 26. Any one of claims 22 to 25, wherein the humanized antibody is administered to the patient in about 30 minutes. The method according to claim 5.
34. 26. Any one of claims 22 to 25, wherein the humanized antibody is reconstituted from a lyophilized formulation. The method described above.
35. 35. The method of claim 34, further comprising reconstituting the humanized antibody into a stable liquid formulation.
36. The patient has a lack of adequate response to corticosteroids or The method of any one of claims 22 to 25, comprising a loss of response to
37. The treatment is measured by the patient's PDAI score or CDAI score. The method according to any one of claims 22 to 25.
38. 2. The patient's PDAI score is reduced by at least 3 points from baseline.
37. The method according to claim 37.
39. The humanized antibody has a heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:
1. The method according to any one of claims 22 to 38.
40. the humanized antibody has a light chain variable region sequence of amino acids 20-131 of SEQ ID NO:2; 40. The method according to any one of claims 22 to 39.
41. The humanized antibody has a heavy chain comprising amino acids 20 to 470 of SEQ ID NO:1 and an amino acid sequence comprising SEQ ID NO:
2. The method of claim 39 or 40, having a light chain comprising amino acids 20 to 238.
42. The method of any one of claims 22 to 41, wherein the humanized antibody is vedolizumab. .
